Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...

Viatris' latest transaction includes three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-par...

Biocon Biologics is set to integrate a major portion of the biosimilars business acquired from Viatris in the current fiscal year, accordin...

Biocon Biologics on Wednesday said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countr...

However, the API sale process, which was launched a couple of months ago, has seen no serious buyers, added multiple people aware of the de...

India's Kotak Mahindra Group asset management arm said on Wednesday it will invest 10.70 billion rupees ($129 million) in Biocon Ltd to hel...

"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...

At the time of announcing the deal to acquire Viatris, BBL had said it would be through a cash payment of USD 2 billion, which would be fun...

The ophthalmology portfolio consists of six new chemical entities (NCEs or molecules) that are under phase 3 trials and will be developed f...

When Biocon said it will buy US-based Viatris Inc's biosimilars business in a transaction valued at $3.34 billion that will increase debt o...

While Viatris has commercialisation rights for the US, Canada, Australia, EU and others, Biocon will be able to commercialise the products ...

The listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...

Biocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...

Biocon Biologics Ltd., a subsidiary of Bengaluru-headquartered Biocon Ltd., has announced that Kixelle, a biosimilar insulin as part co-dev...

Biocon's arm Biocon Biologics and Mylan, a subsidiary of Viatris Inc, have been informed by the USFDA of a deferred action on the BLA for M...

"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard revie...

Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is ex...